Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...

Eli Lilly LLY and Merck MRK are both major global pharmaceutical companies with blockbuster drug portfolios and deep ...

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca ...

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca ...

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral ...

Eli Lilly plans to acquire Loxo Oncology for $8 billion in cash to expand its portfolio of cancer medications, according to CNBC. Loxo Oncology is developing a pipeline of targeted oncology treatments ...

Eli Lilly and Indiana University (IU) have announced a new agreement, under which Lilly will provide up to $40m to IU in ...

The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.25 billion to develop new versions of the sticky molecules in collaboration with Magnet ...